Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

被引：0
|
作者：
M. R. McClung
P. D. Miller
J. P. Brown
J. Zanchetta
M. A. Bolognese
C. L. Benhamou
A. Balske
D. E. Burgio
J. Sarley
L. K. McCullough
R. R. Recker
机构：
[1] Oregon Osteoporosis Center,
[2] Colorado Center for Bone Research,undefined
[3] Groupe de recherche en rhumatologie et maladies osseuses,undefined
[4] University of El Salvador,undefined
[5] Metabolic Research Institute,undefined
[6] Bethesda Health Research,undefined
[7] Institut de Prévention et de Recherche sur l’Ostéoporose,undefined
[8] Abbott Laboratories,undefined
[9] Procter and Gamble Pharmaceuticals,undefined
[10] The Procter and Gamble Company,undefined
[11] Warner Chilcott Pharmaceuticals Inc,undefined
[12] Ben Venue Laboratories,undefined
[13] ICON Clinical Research,undefined
[14] Creighton University,undefined
[15] Osteoporosis Research Center,undefined
来源：
Osteoporosis International | 2012年 / 23卷
关键词：
Bone mineral density; Delayed-release; Enteric-coated; Fracture risk; Osteoporosis; Risedronate; Weekly;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 276
页数：9
相关论文
共 50 条
  • [31] Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS)
    Alroughani, Raed
    Das, Rajiv
    Penner, Natasha
    Pultz, Joe
    Taylor, Catherine
    Eraly, Satish
    PEDIATRIC NEUROLOGY, 2018, 83 : 19 - 24
  • [32] Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
    Alroughani, Raed
    Huppke, Peter
    Mazurkiewicz-Beldzinska, Maria
    Blaschek, Astrid
    Valis, Martin
    Aaen, Gregory
    Pultz, Joe
    Peng, Xiaomei
    Beynon, Vanessa
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [33] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
    M. R. McClung
    J. R. Zanchetta
    A. Racewicz
    C. Roux
    C.-L. Benhamou
    Z. Man
    R. A. Eusebio
    J. F. Beary
    D. E. Burgio
    E. Matzkin
    S. Boonen
    P. Delmas
    Osteoporosis International, 2013, 24 : 293 - 299
  • [34] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
    McClung, M. R.
    Zanchetta, J. R.
    Racewicz, A.
    Roux, C.
    Benhamou, C. -L.
    Man, Z.
    Eusebio, R. A.
    Beary, J. F.
    Burgio, D. E.
    Matzkin, E.
    Boonen, S.
    Delmas, P.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 293 - 299
  • [35] Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability
    Lenczuk, David
    Zinke-Cerwenka, Wilma
    Greinix, Hildegard
    Woelfler, Albert
    Prattes, Juergen
    Zollner-Schwetz, Ines
    Valentin, Thomas
    Lin, Timothy C.
    Meinitzer, Andreas
    Hoenigl, Martin
    Krause, Robert
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (06)
  • [36] Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
    Sandborn, William J.
    Regula, Jaroslaw
    Feagan, Brian G.
    Belousova, Elena
    Jojic, Njegica
    Lukas, Milan
    Yacyshyn, Bruce
    Krzeski, Piotr
    Yeh, Chyon-Hwa
    Messer, Christi A.
    Hanauer, Stephen B.
    GASTROENTEROLOGY, 2009, 137 (06) : 1934 - 1943
  • [37] Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
    Kukulka, Michael
    Nudurupati, Sai
    Perez, Maria Claudia
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (06) : 770 - 780
  • [38] Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: A comparison with a 2.5 mg once-daily dosage regimen
    Hagino, Hiroshi
    Kishimoto, Hideaki
    Ohishi, Hiroaki
    Horii, Sayako
    Nakamura, Toshitaka
    BONE, 2014, 59 : 44 - 52
  • [39] Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women
    Fourcroy, JL
    Berner, B
    Chiang, YK
    Cramer, M
    Rowe, L
    Shore, N
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) : 4137 - 4143
  • [40] Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder
    Pliszka, Steven R.
    Wilens, Timothy E.
    Bostrom, Samantha
    Arnold, Valerie K.
    Marraffino, Andrea
    Cutler, Andrew J.
    Lopez, Frank A.
    DeSousa, Norberto J.
    Sallee, Floyd R.
    Incledon, Bev
    Newcorn, Jeffrey H.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (06) : 474 - 482
12345